Company profile: CPTx
1.1 - Company Overview
Company description
- Provider of programmable, single-stranded DNA-based therapeutics and platforms, including composite programmable therapeutics, antiviral countermeasures and a pipeline of antiviral drugs, programmable DNA nanofabrication, and a non-viral gene delivery platform; enabling precise control of drug presentation to target viruses (including influenza), cancer, and autoimmune disorders.
Products and services
- Composite Programmable Therapeutics: CPTx architects modular single-stranded DNA–based therapeutic particles programmed for precise multi-function control, enabling coordinated targeting and tunable activity to address complex diseases
- Programmable Medicines: CPTx develops clinical-grade medicines that program drug molecule placement and presentation using single-stranded DNA constructs, delivering precision targeting across viruses, cancer, and autoimmune disorders
- Antiviral Therapeutics: CPTx engineers broad-spectrum antiviral drugs derived from composite programmable technology, effective against multiple viruses, including a lead influenza candidate.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CPTx
Pattern Bioscience
HQ: United States
Website
- Description: Provider of biotech diagnostic solutions to combat antibiotic resistance, including Digital Culture Technology, a single-cell analysis platform using digital cell reactors and machine learning to rapidly diagnose complex bacterial infections and determine antibiotic response without traditional culture, and the Pneumonia Action Panel for fast, comprehensive pathogen identification and susceptibility in hospitalized severe pneumonia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pattern Bioscience company profile →
Amicrobe
HQ: United States
Website
- Description: Provider of advanced biomaterials to prevent and treat infections, offering Amicidin-α Surgical gel for clean and clean-contaminated surgical procedures; Amicidin-β Solution for contaminated and infected tissues with tissue cleansing and microbicidal activity; Amicidin-α PFC for military prolonged field settings (up to 72 hours); and Amicidin-β/EF for emergency settings, including trauma and emergency cesarean delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amicrobe company profile →
MSD
HQ: United States
Website
- Description: Provider of medicines, vaccines, biologic therapies, and animal health products as a leading global biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MSD company profile →
ITS Innovation
HQ: United Kingdom
Website
- Description: Provider of synthetic vaccines for mutating viruses using a T-cell vaccine platform that targets conserved viral antigens to direct immune responses, and of pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH, designed to reduce body weight, liver fat, serum lipids, and address liver fat and fibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ITS Innovation company profile →
Venatorx Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective therapies for multi-drug-resistant bacterial and viral infections, including cefepime-taniborbactam for complicated urinary tract infections and potentially hospital-acquired and ventilator-associated bacterial pneumonia; ceftibuten-ledaborbactam etzadroxil for drug-resistant Enterobacterales; and a PBP inhibitor program developing non-beta-lactam molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Venatorx Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CPTx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CPTx
2.2 - Growth funds investing in similar companies to CPTx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CPTx
4.2 - Public trading comparable groups for CPTx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →